90 results
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc
9 Feb 24
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
12:34pm
investigation by the Company as to whether the Executive is or will be in breach of any obligation in this Exhibit C. The Executive will promptly
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc
27 Oct 23
Entry into a Material Definitive Agreement
7:16pm
immediately and shall expire when exercised in full, in the form of Exhibit B attached hereto.
“Proceeding” means an action, claim, suit, investigation … or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened
8-K
EX-10.2
INM
InMed Pharmaceuticals Inc
27 Oct 23
Entry into a Material Definitive Agreement
7:16pm
as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning … is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and shall
8-K
EX-4.2
INM
InMed Pharmaceuticals Inc
27 Oct 23
Entry into a Material Definitive Agreement
7:16pm
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
f
8-K
EX-4.1
INM
InMed Pharmaceuticals Inc
27 Oct 23
Entry into a Material Definitive Agreement
7:16pm
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
f) Restrictions. The Holder
8-K
EX-4.3
khvjtxwf9
27 Oct 23
Entry into a Material Definitive Agreement
7:16pm
8-K
EX-99.1
mec12mnsho
29 Sep 23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
5:18pm
8-K
EX-10.2
tipggwk
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
3:47pm
8-K
EX-4.1
iv7ilsmfhub2w6gqoc
21 Nov 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
7:02pm
8-K
EX-4.2
htjaxyl ow
21 Nov 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
7:02pm
8-K
EX-10.1
1rkh7zh81q5b2ijewg1
21 Nov 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
7:02pm
8-K
EX-10.2
l2pogiag5a1r lnc
21 Nov 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
7:02pm
8-K
EX-4.3
jhyhkft
21 Nov 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
7:02pm
8-K
EX-99.1
d61 0yvtr
17 Nov 22
Regulation FD Disclosure
10:24am
8-K
EX-4.1
fogu7q7 or
13 Sep 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9:59pm